Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imatinib in combination with cytarabine as compared to imatinib alone in patients with first chronic phase chronic myeloid leukemia. A prospective randomised phase III study.

X
Trial Profile

Imatinib in combination with cytarabine as compared to imatinib alone in patients with first chronic phase chronic myeloid leukemia. A prospective randomised phase III study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms HOVON-78-CML
  • Most Recent Events

    • 16 Aug 2014 New source identified and integrated (European Clinical Trials Database record:EudraCT2005-003839-41)
    • 01 Oct 2013 According to the European Clinical Trials database record, trial status is completed.
    • 01 Aug 2013 Results published in the Annals of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top